This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
PHILADELPHIA ― High-frequency deep transcranial magnetic stimulation (TMS) that targets signaling pathways involved in obsessive compulsive disorder (OCD) is showing promise as a novel approach for the treatment of this challenging disorder, new research shows.
“OCD unfortunately is a very disabling disorder for many of the people who have it, and about half of patients who have OCD are not able to recover adequately with currently approved treatments,” Aron Tendler, MD, chief medical officer of Brainsway®, told Medscape Medical News.
Read the article here.